Yes, but as a more conventional small molecule drug it won’t have all the issues that MSB have had. MSB are trying to be the first to bring cell therapy to market and the FDA really doesn’t know how to regulate it. Bisantrene is a typical small molecule drug that the FDA has approved thousands - this make a huge difference to the process as both us and the FDA know what is expected.
-
- There are more pages in this discussion • 913 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
